Lisinopril pills look like
Pro Research Analysisby 
Searched over 200M research papers
Appearance and Impact of Lisinopril Pills
Lisinopril Pill Appearance
Lisinopril, a commonly prescribed medication for hypertension, is available in various generic forms, which can differ in appearance. These differences can include variations in color, shape, and size. Such variations are common among generic medications and can sometimes lead to confusion among patients1.
Patient Perceptions and Preferences
A significant portion of patients rely on the appearance of their pills to ensure they are taking the correct medication. In a survey, 72% of respondents indicated that they depend on the pill's appearance for this purpose. Additionally, a similar percentage of patients expressed a preference for their pills to remain consistent in color (72%), shape (71%), and size (75%) upon refill1. This reliance on visual cues underscores the importance of pill appearance in medication adherence.
Impact of Changes in Pill Appearance
Changes in the appearance of lisinopril pills can lead to various patient responses. For instance, 21% of patients who experienced a change in their pill's appearance thought they had received the wrong medication, and 8% adjusted their medication use as a result1. These findings highlight the potential for decreased adherence and increased anxiety among patients when their medication's appearance changes unexpectedly.
Adherence and Packaging
The packaging of lisinopril can also influence adherence, particularly among older patients. A study comparing daily-dose blister packaging (Pill Calendar) with traditional bottles of loose tablets found that patients using blister packaging refilled their prescriptions more regularly and had higher medication possession ratios (MPRs). Additionally, these patients exhibited better treatment outcomes, such as lower diastolic blood pressure2. This suggests that clear and consistent packaging can enhance adherence and improve health outcomes.
Conclusion
The appearance and packaging of lisinopril pills play a crucial role in patient adherence and perception. Consistency in pill appearance can help ensure that patients take their medication correctly, while thoughtful packaging solutions like daily-dose blister packs can further support adherence, especially in older populations. Standardized pharmacy notification and education policies regarding changes in pill appearance may also help mitigate confusion and improve adherence.
Sources and full results
Most relevant research papers on this topic
A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications
Uniform pill appearance may help increase adherence, but standardized pharmacy notification and education policies may be a more feasible short-term solution.
Observational StudyImpact of medication packaging on adherence and treatment outcomes in older ambulatory patients.
Daily-dose blister packaging (Pill Calendar) improves medication adherence and treatment outcomes in elderly patients compared to traditional bottles of loose tablets.
RCT
Highly CitedFormulation and Evaluation of Lisinopril Double Layer Tablet
Lisinopril double layer tablets with 100 mg fast release layer and 100 mg sustained release layer effectively increase patient compliance and decrease dosing frequency for better hypertension control.
A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.
Combination therapy in a single pill for hypertension significantly increases persistence with prescribed therapy compared to separate two-pill therapy.
Observational StudyHighly CitedEffect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
ACE inhibitor treatment can slow renal disease progression in type II diabetes mellitus patients, with lisinopril showing the most significant benefit for this group.
RCT
Large Human TrialHighly CitedSynthesis and Characterization of Compounds Related to Lisinopril
This study identifies and synthesizes an unknown impurity in lisinopril production, as well as three other European Pharmacopoeia 8.4 impurities, to improve lisinopril quality and control.
Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients
Lisinopril is neutral in its effects on insulin sensitivity, plasma insulin and glucose, and lipoprotein metabolism in patients with essential hypertension.
RCTLisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
Lisinopril effectively lowers blood pressure in elderly patients with hypertension, improves congestive heart failure, reduces mortality and left ventricular dysfunction, and is well-tolerated and well-tolerated by patients with diabetes and hypertension.
Literature ReviewOral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice
Oral lisinopril increases ACE2 in tissues relevant to COVID-19 transmission and pathogenesis, but the addition of losartan prevents these increases in ACE2 levels.
RCT
Animal Study